Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.

Abstract

The aim of this study was to investigate the impact of different KRAS mutations on the inhibitory potential of afatinib and gefitinib in SW48 colorectal cancer cells. The influence of afatinib/gefitinib on cell viability and cell cycle was evaluated in isogenic SW48 KRAS wild-type/mutant cells. Protein levels of phosphorylated/total EGFR, HER-2, HER-3, ERK… (More)
DOI: 10.1097/CAD.0000000000000196

Topics

Cite this paper

@article{Gamba2015EffectOK, title={Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.}, author={Sebastian Gamba and Peter {\vC}amaj and Volker Heinemann and Ruediger Paul Laubender and Yan Wang and Yue Zhao and Sebastian Stintzing and Clemens Albrecht Giessen and Stefan Hubert Boeck and Christoph Haertl and Christiane J Bruns and Dominik Paul Modest}, journal={Anti-cancer drugs}, year={2015}, volume={26 4}, pages={371-8} }